Primary Liver Cancer
Conditions
Keywords
primary liver cancer, hepatitis B virus, anti-virus therapy
Brief summary
This study is working to research the efficacy and significant of the anti-virus therapy in the unresectable Hepatitis B virus (HBV) related primary liver cancer(PLC) so as to establish treatment standards of anti-virus therapy in PLC.
Detailed description
primary liver cancer(PLC)is one of the world's most common malignancies, especially in East-Asian countries.Hepatitis B virus (HBV) infection is associated with 70-90% of PLC cases in China. PLC can develop during any stage of the natural course of chronic HBV infection and anti-virus therapy should be considered during the management of PLC. However, there is no definite guide on when or how to practice the anti-virus therapy, especially in unresectable or inoperable PLC. Because of these facts, research on the significant of the anti-virus therapy in the HBV-related PLC is urgently needed. 200 patients will be randomly assigned to anti-virus therapy group and control gruop.The time to progression(TTP) and overall survival within two years will be used to evaluate the effect of anti-virus therapy on PLC. The aim of this study is to research the efficacy and significant of the anti-virus therapy in the unresectable HBV-related PLC so as to establish treatment standards of anti-virus therapy in PLC.
Interventions
DRUGEntecavir
Entecavir 0.5mg per day
DRUGconventional therapy
conventional therapy including protecting the liver function, anti-tumor and so on
Sponsors
Eastern Hepatobiliary Surgery Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Identify patients with PLC in accordance with the clinical diagnostic criteria of PLC.Patients with PLC shall be diagnosed with or without pathology. It is not appropriate to perform liver resection operation. 2. serum positive HBsAg≥6 months. 3. Criteria of liver function: Child A or B level, serum total bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase ≤ 10 times the upper limit of normal value. 4. hemoglobin≥8.5g/dl, PT-INR≤2.3 or PT\>6 seconds of normal value. 5. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. 6. Patients who can understand this trial, male or female, aged 18-70 voluntarily participate in clinical trials and have signed information consent.
Exclusion criteria
1. Patients with apparent cardiac, pulmonary, cerebric and renal dysfunction, which may affect the treatment of liver cancer. 2. Patients with other diseases which may affect the treatment mentioned here. 3. Patients with medical history of other malignant tumors. 4. Subjects participating in other clinical trials. 5. Women in pregnancy and breast-feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time-to-progression(TTP) | 1,2 and 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS) | 1,2 and 3 years |
| The overall response rate | 1,2 and 3 years |
Countries
China
Outcome results
None listed